Collaboration and Licensing Revenue (Tables)

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2019 and 2018.



	Three Months Ended March 31,
	2019			2018
ZIOPHARM Oncology, Inc.	$	1,166		$	5,377
Ares Trading S.A.	—			2,423
Oragenics, Inc.	203			125
Intrexon T1D Partners, LLC	—			1,328
Intrexon Energy Partners, LLC	977			1,197
Intrexon Energy Partners II, LLC	504			378
Genopaver, LLC	294			1,315
Fibrocell Science, Inc.	383			293
Persea Bio, LLC	(1,272		)	209
Harvest start-up entities (1)	2,723			3,197
Other	992			4,006
Total	$	5,970		$	19,848

(1)

For the three months ended March 31, 2019 and 2018, revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the three months ended March 31, 2018, revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc.

Summary of Deferred Revenue

Deferred revenue consists of the following:



	March 31, 2019		December 31, 2018
Collaboration and licensing agreements	$	65,135	$	63,284
Prepaid product and service revenues	3,157		2,933
Other	2,899		3,547
Total	$	71,191	$	69,764
Current portion of deferred revenue	$	17,149	$	15,554
Long-term portion of deferred revenue	54,042		54,210
Total	$	71,191	$	69,764

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of March 31, 2019 and December 31, 2018, including the estimated remaining performance period as of March 31, 2019.



	Average Remaining Performance Period (Years)	March 31, 2019		December 31, 2018
ZIOPHARM Oncology, Inc.	0.5	$	628	$	1,214
Oragenics, Inc.	5.2	5,669		5,810
Intrexon Energy Partners, LLC	5.0	9,659		10,267
Intrexon Energy Partners II, LLC	5.7	13,556		14,060
Genopaver, LLC	5.0	1,238		1,175
Fibrocell Science, Inc.	5.9	17,192		17,519
Persea Bio, LLC	5.8	4,070		2,697
Harvest start-up entities (1)	5.9	7,260		7,644
Other	2.0	5,800		2,898
Total		$	65,072	$	63,284

(1)

As of March 31, 2019 and December 31, 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.